Holster, Tiina, Elina Urpilainen, Jorma Paavonen, Ulla Puistola, and Mirja Puolakkainen. “Immunological Markers of Chlamydia Trachomatis Infection in Epithelial Ovarian Cancer.” Anticancer Research 43, no. 9 (September 2023): 4037–43. https://doi.org/10.21873/anticanres.16592.
Immunological markers of Chlamydia trachomatis infection in epithelial ovarian cancer
|Author:||Holster, Tiina1,2; Urpilainen, Elina3,4,5; Paavonen, Jorma2;|
1Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
2University of Helsinki, Helsinki, Finland
3Department of Obstetrics and Gynecology, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, Oulu, Finland
4Research Unit of Clinical Medicine, University of Oulu, Oulu, Finland
5Medical Research Center, University of Oulu, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, Oulu, Finland
6Department of Virology, Helsinki University Hospital, HUSLAB, Helsinki, Finland
|Online Access:||PDF Full Text (PDF, 0.6 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe20231023141013
International Institute of Anticancer Research,
|Publish Date:|| 2023-10-23
Background/Aim: Pelvic inflammatory disease (PID) is a risk factor for epithelial ovarian cancer (EOC). Chlamydia trachomatis infection, a major cause of PID, may persist in some women. Serum IgG antibodies to chlamydial TroA and HtrA are more common in ascending or repeat chlamydial infection than in uncomplicated infection. The aim of this study was to explore the role of C. trachomatis infection in EOC by analyzing chlamydial TroA, HtrA and major outer membrane protein (MOMP) IgG serum antibody responses.
Patients and Methods: The study is based on the review of Oulu University Hospital medical records of 162 women diagnosed with EOC between March 2008 and May 2018. Serum IgG antibody responses to recombinant C. trachomatis TroA, HtrA and MOMP were analyzed using enzyme-linked immunoassay. Complete response to the first line therapy and the three-year survival were the study endpoints.
Results: Altogether, 16.7%, 11.1% and 12.3% women were C. trachomatis TroA, HtrA and MOMP IgG positive, respectively. Women with these antibodies were more likely to have a complete response to the first-line treatment, compared to women without these antibodies (63.0% vs. 34.1% for TroA IgG, 50.0% vs. 37.5% for HtrA IgG and 50% vs. 37.3% for MOMP IgG, respectively). The presence of these antibodies predicted better three-year survival.
Conclusion: Women with EOC and positive markers of persistent C. trachomatis infection have better response to the first-line treatment and seem to have better three-year survival.
|Pages:||4037 - 4043|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This study was supported by Helsinki University Hospital Research Funding for M.P. (TYH2021225, TYH 2023329 and Y780020098), Oulu Duodecim Society, Thelma Mäkikyrö Foundation and Oulu University Hospital Research Funding (OYS EVO K77729) for E.U., The Finnish Medical Foundation for T.H., and Jane and Aatos Erkko Foundation for U.P.
© 2023 The Authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).